Clinical trials
catalyst calendar across sponsors →Studies where MAZE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 12 tracked-famous managers (MARSHALL WACE, LLP, CITADEL ADVISORS LLC, HHLR ADVISORS, LTD., Hudson Bay Capital Management LP, TWO SIGMA INVESTMENTS, LP, +7 more) · FINRA short interest 15.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 11 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of MZE782 in Adults With PKUNCT07694440Safety and tolerability based on incidence of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: MZE782, MZE782 · Other: Placebo | Phenylketonuria (PKU) | 38 | Dec 2027 | ≤ 499 d | 2026-07-14 |
| A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseNCT06830629Safety and tolerability as assessed by incidence of adverse events (AEs)Open-label · Treatment | Phase 2 | Recruiting | Drug: MZE829 | Proteinuric Kidney Disease | 74 | Sep 2026 | ≤ 42 d | 2026-07-27 |
| A Randomized Phase 1 of of MZE001 in Healthy VolunteersNCT05249621Number of participants with adverse events as a measure of safety and tolerability of MZE001Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: MZE001, Placebo | Healthy | 121 | 2022-12-21actual | — | 2023-02-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19